Aqtual, Inc.

In a new series, we will be highlighting the “Aqtual” voices of our team members - we seek to share their proudest moments, greatest wins, and biggest learnings. To kick things off, we asked our CEO and Founder, Diana Abdueva what her proudest moment has been since our founding. Leading the charge, Diana has guided Aqtual from groundbreaking science to the brink of launching our first product—a milestone that epitomizes our commitment to transforming healthcare. Stay tuned for more insights from the dedicated voices behind Aqtual. #PrecisionMedicine #AqtualVoices

At Aqtual, we know that great work happens with a little support from our four-legged friends. Whether they are by our side through virtual meetings, or boosting morale during deadlines, our furry friends remind us of the importance slowing down and enjoying the little things in life with tail-wagging enthusiasm. 🐕🦺 From playful pups to wise seniors, here's a look at the beloved dogs that bring a little extra happiness to our days! #PrecisionMedicine #Aqtual

Aqtual is attending the Congress of Clinical Rheumatology (CCR) West this week! Attending the conference and interested in learning more about our PRIMA-102 study and RA Therapy Selection Test we are developing? Be sure to reach out to Brad Hoolahan to set up some time to chat! #CCRWest #Rheumatology https://lnkd.in/eJVkAufN

Headed to Coalition of State Rheumatology Organizations (CSRO) Advocacy Conference in Nashville, TN this week? Be sure to stop by our exhibit to say hi to Signe Fransen and Brad Hoolahan. See you there! #CSRO2024

We are excited to announce our publication in Communications Biology, a Nature portfolio journal. The paper, ‘Extracting regulatory active chromatin footprint from cell-free DNA,’ highlights the potential of our proprietary platform for new clinical applications across major disease areas. Chronic disease management today is inefficient, often relying on trial and error. With over 90% of U.S. healthcare spending on chronic conditions, our technology aims to transform treatment through earlier diagnoses, personalized therapies, and non-invasive monitoring. Congratulations to the study authors and the Aqtual team for this groundbreaking work! Check out our paper here: https://lnkd.in/e9avCvyT #Aqtual #PrecisionMedicine

We are excited to welcome Jennifer Berman to our growing team! As Vice President, Research & Development, Jen will be responsible for the strategic and functional leadership of a multi-function R&D team driving technical innovation and clinical product development based on Aqtual’s proprietary chromatin capture biochemistry platform. To celebrate Jen’s appointment, we asked her what excited her the most about joining us. #PrecisionMedicine #AqtualVoices

On September 11th, Aqtual's CEO Diana Abdueva will join industry leaders at LSX World Congress USA (LSX - partnering for Life Science eXecutives) in Boston to discuss her journey to raising a Series A to support auto-immune disease research. If you are attending the event, be sure to join us on September 11th at 1:45pm! #LSXUSA #PrecisionMedicine

Last month, members of our team attended the Florida Society of Rheumatology Annual Meeting, where we had the opportunity to engage with industry leaders, share insights, and explore the latest advancements in rheumatology. Thank you to Signe Fransen and Brad Hoolahan for your participation, and thank you to everyone who stopped by our booth to say hello. Until next year!

Recently, our CEO and Co-Founder, Diana Abdueva, Ph.D sat down with Keith Robison, Ph.D. from the Omics! Omics! Blog to delve into liquid biopsies, cfDNA and the unique and innovative space Aqtual, Inc. occupies as we strive to simplify treatment strategies and address the critical unmet needs in chronic disease management. To learn more about what we’re doing and Dr. Abdueva’s path to Aqtual, you can read the full blog here: https://lnkd.in/eEvqkJHf

Aqtual, Inc.'s cofounder and CEO, Diana Abdueva, PhD and Vice President of Translational Research and Strategic Partnerships Maggie Louie recent sat down to discuss the incredible possibilities of liquid biopsy beyond cancer with the Mendelspod Podcast. Anyone can tune in and listen to learn about our first assay for rheumatoid arthritis, our proprietary technology and what's on the horizon for Aqtual. Listen here: